
Product Data Sheet

Product Name: RPT193
Cat. No.: GC67869

Chemical Properties

Cas. No. 2366152-15-8

Formula $C_{27}H_{34}Cl_3N_5O_2$

M.Wt 566.95

Solubility Methanol : 250 mg/mL (440.96 mM; Need ultrasonic); DMSO : 100 mg/mL (176.38 mM; Need ultrasonic) Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

RPT193 is an orally active inhibitor of **CCR4**, blocks the recruitment of Th2 inflammatory immune cells into inflamed tissues. RPT193 can be used for allergic inflammation in atopic dermatitis, asthma, and other diseases research^[1].

RPT193 (1 nM-10 μ M) inhibits Th2 cells chemotaxis or migration with IC₅₀s of ~370 nM^[2].

RPT193 (100 mg/kg; p.o.; once daily; 2 d, 1 d before OVA-challenge) reduces skin inflammation in an acute ovalbumin (OVA)-induced atopic dermatitis model in mice^[2].

Animal Model: Acute ovalbumin (OVA)-induced atopic dermatitis model in mouse^[2]

Dosage: 100 mg/kg

Administration: Oral gavage; once daily; for 2 days, started 1 day before OVA-challenge (in mouse ear)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Result: Decreased the ear thickness significantly.

[1]. Bissonnette R, et al. RPT193, an oral CCR4 inhibitor: Efficacy results from a randomized, placebo-controlled Phase 1b monotherapy trial in patients with moderate-to-severe atopic dermatitis[C]//EXPERIMENTAL DERMATOLOGY. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY, 2021, 30: 40-41.

[2]. Cheng L, et al. Development and first-in-human characterization of a potent oral CCR4 antagonist for the treatment of atopic dermatitis[C]//Journal of Investigative Dermatology. STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA: ELSEVIER SCIENCE INC, 2020, 140(7): S77-S77.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA